Abstract
Background:Obesity and overweight affect more than half of the US population and are associated with a number of diseases. Rimonabant, a cannabinoid receptor 1 blocker in the endocannabinoid (EC) system, was indicated in Europe for the treatment of obesity and overweight patients with associated risk factors but withdrawn on Jan, 2009 because of side effects. Many studies have reported the effects of rimonabant on gastrointestinal (GI) motility and food intake. The aims of this review are: to review the relationship of EC system with GI motility and food intake;to review the studies of rimonabant on GI motility, food intake and obesity;and to report the tolerance and side effects of rimonabant. Methods:the literature (Pubmed database) was searched using keywords: rimonabant, obesity and GI motility. Results:GI motility is related with appetite, food intake and nutrients absorption. The EC system inhibits GI motility, reduces emesis and increases food intake; Rimonabant accelerates gastric emptying and intestinal transition but decreases energy metabolism and food intake. There is rapid onset of tolerance to the prokinetic effect of rimonabant. The main side effects of rimonabant are depression and GI symptoms. Conclusions:Rimonabant has significant effects on energy metabolism and food intake, probably mediated via its effects on GI motility.
Highlights
Obesity is widely recognized as a serious health problem with increasing prevalence across the US and the world, and is one of the leading causes of preventable deaths [1]
GI motility is related with appetite, food intake and nutrients absorption
The results showed reduced hunger and caloric intake with all types of food and reduced body weight with one-week treatment of rimonabant
Summary
Obesity is widely recognized as a serious health problem with increasing prevalence across the US and the world, and is one of the leading causes of preventable deaths [1]. The EC system inhibits GI motility, reduces emesis and increases food intake; Rimonabant accelerates gastric emptying and intestinal transition but decreases energy metabolism and food intake. A number of studies have shown that rimonabant, an antagonist of the CB-1 receptor, exerts significant effects on GI motility and energy metabolism.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
